Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
This page describes ibogaine as a plant-derived psychedelic that some researchers are studying for addiction, depression, and PTSD. It says ibogaine can cause strong hallucinations that start within hours and may last up to 24 hours. The page reports some studies and a 2022 review that suggest ibogaine may reduce…
In this rat study, animals got a single injection of ibogaine at 20 mg/kg or 40 mg/kg and the researchers measured three neurotrophic factors (GDNF, BDNF, NGF) in four brain regions (VTA, prefrontal cortex, nucleus accumbens, substantia nigra) at 3 and 24 hours. The main changes appeared at 24 hours:…
Researchers reviewing ibogaine and its chemical relatives say these drugs point to a new way to treat substance use disorders by blocking a brain receptor called α3β4 nicotinic acetylcholine receptor (nAChR). Animal studies found ibogaine and some derivatives reduced self-use of drugs like morphine, cocaine, alcohol, and nicotine. But ibogaine…
